Enfusion (NYSE:ENFN) Hits New 12-Month High Following Analyst Upgrade

Enfusion, Inc. (NYSE:ENFN) shares hit a new 52-week high during mid-day trading on Monday after Piper Sandler raised their price target on the stock from $10.00 to $11.50. Piper Sandler currently has a neutral rating on the stock. Enfusion traded as high as $11.50 and last traded at $11.50, with a volume of 224 shares trading hands. The stock had previously closed at $10.63.

Separately, Stifel Nicolaus boosted their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $10.25.

Insider Buying and Selling at Enfusion

In other Enfusion news, COO Neal Pawar sold 21,801 shares of Enfusion stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 36.44% of the company’s stock.

Hedge Funds Weigh In On Enfusion

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Enfusion by 7.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after acquiring an additional 70,367 shares during the period. Wellington Management Group LLP boosted its position in Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock valued at $9,265,000 after acquiring an additional 61,032 shares during the last quarter. State Street Corp lifted its stake in Enfusion by 2.3% in the third quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after buying an additional 21,729 shares during the period. Impax Asset Management Group plc boosted its stake in Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock worth $6,424,000 after acquiring an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC grew its stake in shares of Enfusion by 21.8% in the 2nd quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock valued at $5,227,000 after buying an additional 110,000 shares during the period. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Enfusion Stock Up 0.6 %

The stock has a market cap of $1.36 billion, a price-to-earnings ratio of 264.57, a PEG ratio of 3.98 and a beta of 0.97. The stock has a 50 day simple moving average of $9.74 and a 200 day simple moving average of $9.02.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.